Top

Published in:

01-06-2018 | Original Article

Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner

Authors: Fei Wu, Yun Lin, Peng Cui, Hongyun Li, Lechao Zhang, Zeqiang Sun, Shengliang Huang, Shun Li, Shiming Huang, Qingli Zhao, Qingyong Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Abstract

Purpose

At least to date, no effective treatment for advanced castration-resistant prostate cancer (CRPC) has been established. Recent studies indicated that cell division cycle 20 homolog (Cdc20) overexpression is associated with poor prognosis in patients with castration-resistant prostate cancer. However, the mechanism of Cdc20 in the development of docetaxel resistance in CRPC remains elusive.

Methods

In this study, the transcription of Cdc20 was confirmed in three independent CRPC cell lines derived from different tissues, including LNCaP, PC3, and DU145. Docetaxel resistant (DR) cell lines were generated within the background of DU145 and PC3. The protein levels of Cdc20 and the biological phenotype were detected in both wild-type and DR cell lines. To further explore the mechanism of Cdc20 overexpression, stable cell lines with Cdc20 or Bcl-2 interacting mediator of cell death (Bim) deprivation were generated and examined for biological parameters. In addition, a specific Cdc20 inhibitor was used in DR cell lines to explore the potential solution for docetaxel resistant CRPC.

Results

Here, we identified Cdc20 is overexpressed in docetaxel resistant CRPC cell lines, including LNCaP, PC3, and DU145. We also reported that DR cell lines, which mimic the recurrent prostate cancer cells after docetaxel treatment, have higher levels of Cdc20 protein compared with the CRPC cell lines. Interestingly, the protein levels of Bim, an E3 ligase substrate of Cdc20, were decreased in DR cell lines compared with the wild-type, while the mRNA levels were similar. More importantly, in DR cell lines, the biological phenotype induced by Cdc20 deletion could be significantly reversed by the additional knockdown of Bim. As a result, docetaxel resistant prostate cancer cells treated with the pharmacological Cdc20 inhibitor became sensitive to docetaxel treatment.

Conclusions

In conclusion, our data collectively demonstrated that Cdc20 overexpression facilitates the docetaxel resistant of the CRPC cell lines in a Bim-dependent manner. Furthermore, additionally targeting Cdc20 might be a promising solution for the treatment of the CRPC with docetaxel resistance.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386CrossRef

Mitchell T, Neal DE (2015) The genomic evolution of human prostate cancer. Br J Cancer 113:193–198CrossRefPubMedPubMedCentral

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642CrossRefPubMed

Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 195:1444–1452CrossRefPubMed

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R (2017) Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol. https://doi.org/10.1016/j.eururo.2017.10.002 CrossRefPubMed

Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562–1571CrossRefPubMed

Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W (2015) Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther 151:141–151CrossRefPubMedPubMedCentral

Gayyed MF, El-Maqsoud NM, Tawfiek ER, El Gelany SA, Rahman MF (2016) A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage. Tumour Biol 37:749–762CrossRefPubMed

Mao Y, Li K, Lu L, Si-Tu J, Lu M, Gao X (2016) Overexpression of Cdc20 in clinically localized prostate cancer: relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark 16:351–358CrossRefPubMed

10.

Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q, Zhang J (2017) Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett 385:207–214CrossRefPubMed

11.

Replogle-Schwab TS, Schwab ED, Pienta KJ (1997) Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res 17:4535–4538PubMed

12.

Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W (2014) APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell 29:377–391CrossRefPubMedPubMedCentral

13.

Shukla S, Saxena S, Singh BK, Kakkar P (2017) BH3-only protein BIM: an emerging target in chemotherapy. Eur J Cell Biol 96:728–738CrossRefPubMed

14.

Peters JM (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7:644–656CrossRefPubMed

15.

Hayes MJ, Kimata Y, Wattam SL, Lindon C, Mao G, Yamano H, Fry AM (2006) Early mitotic degradation of Nek2A depends on Cdc20-independent interaction with the APC/C. Nat Cell Biol 8:607–614CrossRefPubMed

16.

Yu H (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 27:3–16CrossRefPubMed

17.

Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Lu M, Peng S, Qiu J, Gao X (2016) Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol 49:1679–1685CrossRefPubMed

18.

Um HD (2016) Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget 7:5193–5203CrossRefPubMed

19.

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K (2010) IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115:2430–2440CrossRefPubMed

20.

Ridinger-Saison M, Evanno E, Gallais I, Rimmele P, Selimoglu-Buet D, Sapharikas E, Moreau-Gachelin F, Guillouf C (2013) Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ 20:1268–1278CrossRefPubMedPubMedCentral

Title: Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner
Authors: Fei Wu
Yun Lin
Peng Cui
Hongyun Li
Lechao Zhang
Zeqiang Sun
Shengliang Huang
Shun Li
Shiming Huang
Qingli Zhao
Qingyong Liu
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3578-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer